Fusion Antibodies PLC (FAB) - Net Assets
Based on the latest financial reports, Fusion Antibodies PLC (FAB) has net assets worth GBX726.00K GBX (≈ $88.33 USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.81 Million ≈ $220.47 USD) and total liabilities (GBX1.09 Million ≈ $132.13 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Fusion Antibodies PLC carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX726.00K |
| % of Total Assets | 40.07% |
| Annual Growth Rate | 6.45% |
| 5-Year Change | -85.91% |
| 10-Year Change | -54.08% |
| Growth Volatility | 282.35 |
Fusion Antibodies PLC - Net Assets Trend (2006–2025)
This chart illustrates how Fusion Antibodies PLC's net assets have evolved over time, based on quarterly financial data. Also explore Fusion Antibodies PLC (FAB) total assets for the complete picture of this company's asset base.
Annual Net Assets for Fusion Antibodies PLC (2006–2025)
The table below shows the annual net assets of Fusion Antibodies PLC from 2006 to 2025. For live valuation and market cap data, see how much is Fusion Antibodies PLC worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | GBX669.00K ≈ $81.40 |
-62.69% |
| 2024-03-31 | GBX1.79 Million ≈ $218.16 |
+59.66% |
| 2023-03-31 | GBX1.12 Million ≈ $136.64 |
-69.52% |
| 2022-03-31 | GBX3.68 Million ≈ $448.24 |
-22.39% |
| 2021-03-31 | GBX4.75 Million ≈ $577.57 |
-1.35% |
| 2020-03-31 | GBX4.81 Million ≈ $585.48 |
-10.12% |
| 2019-03-31 | GBX5.35 Million ≈ $651.44 |
-18.57% |
| 2018-03-31 | GBX6.58 Million ≈ $800.00 |
+285.43% |
| 2017-03-31 | GBX1.71 Million ≈ $207.56 |
+17.08% |
| 2016-03-31 | GBX1.46 Million ≈ $177.28 |
+760.64% |
| 2015-03-31 | GBX169.29K ≈ $20.60 |
+937.34% |
| 2014-03-31 | GBX16.32K ≈ $1.99 |
-67.44% |
| 2013-03-31 | GBX50.13K ≈ $6.10 |
+168.67% |
| 2012-03-31 | GBX-73.00K ≈ $-8.88 |
-122.60% |
| 2011-03-31 | GBX323.00K ≈ $39.30 |
-37.16% |
| 2010-03-31 | GBX514.00K ≈ $62.54 |
+173.40% |
| 2009-03-31 | GBX188.00K ≈ $22.87 |
-71.30% |
| 2008-03-31 | GBX655.00K ≈ $79.69 |
+7.73% |
| 2007-03-31 | GBX608.00K ≈ $73.98 |
+198.04% |
| 2006-03-31 | GBX204.00K ≈ $24.82 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fusion Antibodies PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1146700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX4.20 Million | 627.35% |
| Other Components | GBX7.94 Million | 1186.70% |
| Total Equity | GBX669.00K | 100.00% |
Fusion Antibodies PLC Competitors by Market Cap
The table below lists competitors of Fusion Antibodies PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Centaur Media
LSE:CAU
|
$195.44K |
|
Oriole Resources PLC
LSE:ORR
|
$195.63K |
|
East Star Resources PLC
LSE:EST
|
$196.57K |
|
Ground Rents Income Fund PLC
LSE:GRIO
|
$197.88K |
|
noco-noco Inc. Ordinary Share
NASDAQ:NCNC
|
$192.96K |
|
Sprott Physical Uranium Trust
TO:U-U
|
$192.76K |
|
Graphjet Technology
NASDAQ:GTI
|
$192.60K |
|
Afine Investments Ltd
JSE:ANI
|
$192.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fusion Antibodies PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,793,000 to 669,000, a change of -1,124,000 (-62.7%).
- Net loss of 1,713,000 reduced equity.
- New share issuances of 555,000 increased equity.
- Other factors increased equity by 34,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.71 Million | -256.05% |
| Share Issuances | GBX555.00K | +82.96% |
| Other Changes | GBX34.00K | +5.08% |
| Total Change | GBX- | -62.69% |
Book Value vs Market Value Analysis
This analysis compares Fusion Antibodies PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2006.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10265.42x to 2006.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | GBX0.00 | GBX14.00 | x |
| 2014-03-31 | GBX0.00 | GBX14.00 | x |
| 2015-03-31 | GBX0.01 | GBX14.00 | x |
| 2016-03-31 | GBX0.07 | GBX14.00 | x |
| 2017-03-31 | GBX0.08 | GBX14.00 | x |
| 2018-03-31 | GBX0.41 | GBX14.00 | x |
| 2019-03-31 | GBX0.24 | GBX14.00 | x |
| 2020-03-31 | GBX0.22 | GBX14.00 | x |
| 2021-03-31 | GBX0.19 | GBX14.00 | x |
| 2022-03-31 | GBX0.14 | GBX14.00 | x |
| 2023-03-31 | GBX0.04 | GBX14.00 | x |
| 2024-03-31 | GBX0.03 | GBX14.00 | x |
| 2025-03-31 | GBX0.01 | GBX14.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fusion Antibodies PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -256.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.18%
- • Asset Turnover: 1.49x
- • Equity Multiplier: 1.98x
- Recent ROE (-256.05%) is below the historical average (-174.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -1555.82% | -115.74% | 1.33x | 10.08x | GBX-471.75K |
| 2014 | 0.00% | -15.70% | 2.30x | 0.00x | GBX-113.17K |
| 2015 | -50.27% | -9.36% | 2.45x | 2.19x | GBX-102.04K |
| 2016 | 79.21% | 77.91% | 0.79x | 1.28x | GBX1.01 Million |
| 2017 | 7.03% | 6.27% | 0.89x | 1.26x | GBX-50.64K |
| 2018 | -10.65% | -26.01% | 0.37x | 1.10x | GBX-1.36 Million |
| 2019 | -23.62% | -57.95% | 0.35x | 1.17x | GBX-1.80 Million |
| 2020 | -14.48% | -17.89% | 0.64x | 1.26x | GBX-1.18 Million |
| 2021 | -61.07% | -69.60% | 0.71x | 1.23x | GBX-3.37 Million |
| 2022 | -32.57% | -25.01% | 0.98x | 1.33x | GBX-1.57 Million |
| 2023 | -231.17% | -89.49% | 1.41x | 1.84x | GBX-2.71 Million |
| 2024 | -124.15% | -195.95% | 0.47x | 1.35x | GBX-2.41 Million |
| 2025 | -256.05% | -87.18% | 1.49x | 1.98x | GBX-1.78 Million |
Industry Comparison
This section compares Fusion Antibodies PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,844,150
- Average return on equity (ROE) among peers: -176.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fusion Antibodies PLC (FAB) | GBX726.00K | -1555.82% | 1.50x | $193.60K |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more